Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is an allergenic extract product manufactured by Nelco Laboratories, Inc. formulated as an injectable solution. [2, 5] The product is a combination of five components: allergens from Ctenocephalides canis (dog flea) and Ctenocephalides felis (cat flea) are the primary active ingredients, combined with tragacanth gum, karaya gum, and acacia gum. [10] While the gums can function as excipients, they are also recognized as potential allergens themselves. [4, 8, 17] The product is indicated for both diagnostic testing (e.g., skin tests) and for therapeutic use in allergen-specific immunotherapy (hyposensitization) for patients with allergic disease confirmed by history and skin test reactivity. [3, 11] The mechanism of action for immunotherapy involves the repeated administration of the allergens to desensitize the immune system, leading to an increase in blocking IgG antibodies and a reduction in the IgE-mediated response that causes allergic symptoms. [3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acacia gum allergen extract + ctenocephalides canis allergen extract + ctenocephalides felis allergen extract + karaya gum allergen extract + tragacanth gum allergen extract.